Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease

Bone Marrow Transplantation

Volumn 26, Issue 4, 2000, Pages 445-449

  van Besien, K ^a   Bartholomew, A ^a   Stock, W ^a   Peace, D ^a   Devine, S ^a   Sher, D ^a   Sosman, J ^a   Chen, Y H ^a   Koshy, M ^a   Hoffman, R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Allogeneic transplantation; Fludarabine; Renal failure; Sickle cell disease

Indexed keywords

CORTICOSTEROID; ERYTHROPOIETIN; FLUDARABINE; FOLINIC ACID; HYDROXYUREA; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CAUSE OF DEATH; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; ETHNIC DIFFERENCE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; PAIN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; SICKLE CELL ANEMIA; SPLENECTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0033836980     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702518     Document Type: Article

References (31)

1. Bone marrow transplantation for sickle cell disease
2. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium
3. Improved survival in homozygous sickle cell disease: Lessons from a cohort study
4. Bone marrow transplantation in sickle cell anemia - The dilemma of choice
5. Mortality in sickle cell disease. Life expectancy and risk factors for early death
6. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
7. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
8. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for myeloablative conditioning
9. Tacrolimus and mini-dose methotrexate for prevention of acute graft-vs-host disease after matched unrelated donor transplantation
10. Risk factors for acute graft-versus-host disease in allogeneic blood stem cell transplant recipients
11. Effective clearance of methotrexate using high-flux hemodialysis membranes
12. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, cyclophosphamide. Experience in 44 consecutive patients
13. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
14. Stem cell transplantation for a highly sensitized patient
15. Bone marrow transplantation in adult thalassemic patients
16. Attitudes toward allogeneic transplantation among adults with sickle cell disease
17. High dose melphalan allows durable engraftment of allogeneic bone marrow
18. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: Alloengraftment with potential preservation of fertility
19. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
20. Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus
21. A prospective randomized trial of peripheral blood stem cells or bone marrow for patients undergoing allogeneic transplantation for hematologic malignancies
22. Microdose methotrexate vs methylprednisolone in combination with tacrolimus for prevention of acute graft-vs-host disease (gvhd) after allogeneic blood stem cell transplantation
23. Melphalan and purine analog containing preparative regimens. Less intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
24. Is race a risk factor for allogeneic marrow transplantation?
25. Graft-versus-host disease. Possible higher risk for African American patients
26. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive crisis
27. The pathophysiology of graft vs host disease
28. Bone marrow versus peripheral blood allografts: An evaluation of the donor experience in a Canadian multicentre randomized trial
29. Mixed chimerism: Preclinical studies and clinical applications
30. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood
31. Barriers to bone marrow transplantation for sickle cell anemia